Evaluation of Adalimumab Biosimilar (Exemptia: ZRC 3197) in treatment of Psoriatic Arthritis with concomitant moderate to severe chronic plaque psoriasis- An open labelled prospective pilot case series

Name: Evaluation of Adalimumab Biosimilar (Exemptia: ZRC 3197) in treatment of Psoriatic Arthritis with concomitant moderate to severe chronic plaque psoriasis- An open labelled prospective pilot case series
Creator: Sujay Khandpur
Published: 2019-12-21T14:18:52.484Z
Keywords: Biologicals, Psoriasis

Khandpur, Sujay; Sondhi, Prateek; taneja, neha; Sharma, Preeti; Das, Dayasagar; Sharma, Alpana; Sreenivas, V

doi:10.17632/7bk9p3624z.1

Evaluation of Adalimumab Biosimilar (Exemptia: ZRC 3197) in treatment of Psoriatic Arthritis with concomitant moderate to severe chronic plaque psoriasis- An open labelled prospective pilot case series

Published: 21 December 2019| Version 1 | DOI: 10.17632/7bk9p3624z.1

Contributors:

Sujay Khandpur, Prateek Sondhi, neha taneja, Preeti Sharma, Dayasagar Das, Alpana Sharma, V Sreenivas

Description

Supplemental Figure 1. Change in median PASI score with time on adalimumab biosimilar (Exemptia) Supplemental Figure 2: Change in median DAPSA, IGA and PGA score (for skin and joint disease) with time on adalimumab biosimilar (Exemptia)

Files

Institutions

All India Institute of Medical Sciences

Evaluation of Adalimumab Biosimilar (Exemptia: ZRC 3197) in treatment of Psoriatic Arthritis with concomitant moderate to severe chronic plaque psoriasis- An open labelled prospective pilot case series

Description

Files

Institutions

Categories

Licence